An investigational oral therapy from PTC Therapeutics called PTC518 safely and effectively reduces levels of the mutant huntingtin protein…
Articles by Steve Bryson, PhD
Scientists at the Broad Institute of MIT and Harvard have engineered a harmless adeno-associated virus (AAV) that can efficiently reach…
Two types of orally available small molecules ameliorated symptoms and slowed progression of Huntington’s disease in a mouse model,…
Excessive CAG repeats, the genetic defect that causes Huntington’s disease, lead to processing errors and the production of unexpected…
In a biomarker study, scientists in South Korea found that levels of two proteins — neurofilament light chain (NfL) and…
Neurologists in the U.S. are optimistic about the potential for a new treatment for Huntington’s disease, but emphasize the…
Forms of mutant huntingtin (mHTT) protein that don’t clump initially drive early disease progression in people with Huntington’s disease,…
People with Huntington’s disease were found to have a widespread deficiency of selenium — a trace mineral found…
The U.S. Food and Drug Administration (FDA) will review Neurocrine Biosciences’ application of a new oral granule formulation of…
Increased levels of the stress response protein MTF1 suppressed the toxic effects of the mutant huntingtin (mHTT) protein — the…